In bid to attract more R&D innovation, Europe looks to rewrite its pharma legislation

Pharma’s love affair with the US may see a slight turn of heart in the near future as Europeans look to rewrite their pharmaceutical legislation before the end of 2022, at least in part to make the region more attractive and less burdensome for industry. A few of the major…

Read the source article at endpts.com
2021-09-29 15:03:03